EP0458909A1 - Oligonukleotid-primer-paare zur amplifizierung eines gens, unabhängig von der sequenz und verfahren zu deren verwendung - Google Patents

Oligonukleotid-primer-paare zur amplifizierung eines gens, unabhängig von der sequenz und verfahren zu deren verwendung

Info

Publication number
EP0458909A1
EP0458909A1 EP19900906003 EP90906003A EP0458909A1 EP 0458909 A1 EP0458909 A1 EP 0458909A1 EP 19900906003 EP19900906003 EP 19900906003 EP 90906003 A EP90906003 A EP 90906003A EP 0458909 A1 EP0458909 A1 EP 0458909A1
Authority
EP
European Patent Office
Prior art keywords
primer pair
dna
target dna
oligonucleotide primer
pcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19900906003
Other languages
English (en)
French (fr)
Inventor
Mark P. Pasek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of EP0458909A1 publication Critical patent/EP0458909A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA

Definitions

  • the present invention relates to methods for amplifying isolated nucleic acid sequences, particularly DNA sequences, whose nucleotide sequences are unknown.
  • the invention also relates to oligonucleotide primer pairs that may be employed in the amplification methods of the present invention.
  • genes and the DNA which encodes them is, in some instances, limited by the amount of starting material available for analysis.
  • the successful isolation of a single copy chromosomal gene in the human genome requires the painstaking process of creating a human genomic library and screening millions of genomic clones. Such a screening process would undoubtedly utilize hybridization techniques that employ one or more oligonucleotides.
  • oligonucleotides would be designed based on some known partial DNA sequence of the gene or on a known partial amino acid sequence of the protein encoded by the desired gene. If and when the clone corftaining the desired gene is finally isolated, the clone must then be replicated before a useful quantity of the gene is obtained. If the genomic library is contained in a vector in which the production of large quantities of the gene is not practical (in a bacteriophage, for example) , the gene, once isolated, must be removed from the first vector and subcloned into a more suitable second vector (such as a plasmid) .
  • a more suitable second vector such as a plasmid
  • PCR amplification involves the synthesis of two oligonucleotide primers that are complementary to specific sequences that flank the DNA segment to be amplified. Initially, the double- stranded DNA is heat denatured into single strands. The primers are then added, and allowed to anneal to their complementary sequences. The primers hybridize to opposite strands at opposite ends of the target DNA sequence. DNA replication is then effected by the addition of DNA polymerase and proceeds across the region between the primers, effectively doubling the amount of that DNA sequence. Since the replicated sequences are also complementary to the added primers, each successive round of replication essentially doubles the amount of DNA synthesized in the previous cycle.
  • PCR is a technique enabling those of skill in the art to obtain useful quantities of specific, known DNA sequences heretofore available only in minute amounts.
  • a main drawback associated with the PCR technique was the thermolability of the Klenow fragment of E.coli DNA polymerase I used to catalyze the DNA replication. Because heat denaturation is required to separate the newly synthesized strands at each cycle of replication, fresh Klenow fragment had to be added during each cycle. Such a process was tedious, error- prone and costly.
  • thermostable DNA polymerase has been purified from the thermophilic bacterium Thermus aquaticus [European patent application 258,017; R. K. Saiki et al., "Primer-Directed Enzymatic 1 Amplification of DNA with a Thermostable DNA Polymerase", Science, 239, pp. 487-91 (1988) ]*.
  • This "Tag” polymerase is stable at temperatures up to 95°C and is thus ideally suited for PCR.
  • the use of Tag obviated the need for repeated additions of DNA polymerase and paved the way for automated PCR [DNA Thermal Cycler, Perkin-Elmer/Cetus, Norwalk, CT] .
  • IPCR inverted PCR
  • the circular DNA is then linearized by cleavage at a site that lies within the boundaries of the known sequences.
  • Oligonucleotide primers corresponding to the ends of the known sequence are synthesized in opposite orientation from that used in normal PCR because the known sequence has been inverted and now flanks the unknown DNA sequence. These primers are then used to amplify the unknown sequences.
  • PCR technology is still limited because the oligonucleotide primers must be synthesized based on some specific known sequence which flanks the DNA to be amplified. [See, for example, T. L. Bugawan et al., "The Use of Non- Radioactive Oligonucleotide Probes to Analyze Enzymatically Amplified DNA for Prenatal Diagnosis and Forensic HLA Typing", Bio/Technology. 6, pp. 943-47 (1988).] Therefore, different oligonucleotides must be synthesized every time a different sequence is amplified. Moreover, PCR cannot be employed in situations where no sequence information is available.
  • the present invention solves the problems referred to above by providing sequence-independent gene amplification methods. These methods allow for the amplification of any isolated double stranded DNA segment even in the absence of information regarding its nucleotide sequence or the sequence of its flanking regions.
  • the methods of this invention are especially useful in producing clonable quantities of DNA or cDNA when such amounts are not available in nature.
  • the present invention also provides methods for amplifying any isolated nucleic acid fragment.
  • the invention also relates to "universal oligonucleotide primer pairs" which are used in the sequence-independent gene amplification methods of this invention.
  • the methods of this invention are advantageously used when about 100 molecules or less of one or more target DNA sequences are initially available.
  • the universal oligonucleotide primer pairs of the present invention are ligated onto the ends of the DNA fragment to be amplified to create specific targets for PCR. In this manner, analyzable and clonable quantities of DNA may be synthesized.
  • the universal oligonucleotide primer pairs of this invention and the methods which employ them may be used to amplify any double-stranded DNA segment or group of DNA segments. These methods produce useful quantities of the segment(s) faster and at less cost than conventional methods.
  • the methods of this invention are useful in a wide variety of situations such as amplifying unknown nucleic acid sequences from a low titer of an infective agent, producing useful quantities of cDNA initially synthesized from trace amounts of tissue and directly producing useful amounts of cDNA or DNA from an isolated reco binant clone.
  • Figure 1 depicts a photograph of an agarose gel on which target DNA sequences amplified by a method of this invention have been electrophoresed.
  • the present invention relates to methods for amplifying nucleic acid molecules whose nucleotide sequence is unknown.
  • the methods of this invention are especially useful in amplifying nucleic acid sequences which are present in minute amounts.
  • the invention also relates to pairs of complementary oligonucleotides which are useful in the methods of this invention.
  • universal primer pairs refer to the complementary oligonucleotide pairs of this invention and are used interchangeably.
  • the individual single-stranded oligonucleotides which make up the primer pairs are referred to as "primer pair members" or "linker pair members”.
  • target DNA DNA sequence to be amplified
  • linkered target DNA refers to the product of a ligation between the universal primer pairs of this invention and the target DNA.
  • biological sample refers to any tissue, organ or body fluid sample obtained from any animal, especially a human.
  • patient refers to any animal, particularly a human being.
  • the universal primer pairs of this invention may range in length from about 12 to about 40 nucleotides. They are preferably about 20 nucleotides in length. Each member of the primer pair is substantially equal in length and at least 70% complementary to the other member of the pair. Most preferably, the individual members of the primer pair are exactly the same length and are 100% complementary. There are no specific nucleotide sequence requirements for the universal primer pairs of the present invention. However, it should be understood that certain structural requirements should be considered in order for the primer pairs to be most useful in the methods of this invention.
  • the structural factors that should be considered in designing the primer pairs include the melting temperature of the primer pair, the amount of self- complementarity within each individual member of the pair, the state of phosphorylation of the 5* ends of the primer pair members and the length of the individual members of the pair. Each of these factors will have an effect on the efficiency of the amplification reaction, which, in turn, will effect the maximum amount of DNA that may be produced by the methods of the invention.
  • the melting temperature of the primer pair is the temperature at which hydrogen bonds, which normally hold the pair together, are destroyed. Above this temperature, the individual pair members separate and exist in solution as single-stranded DNA.
  • the primer pair should have a melting temperature lower than the melting temperature of the target DNA sequences to be amplified. Most preferably, the melting temperature of the primer pair will be below about 70°C.
  • the melting temperature of the universal primer pairs of the present invention may be calculated by assigning a 4°C contribution to each G-C base pair, a 2°C contribution to each A-T base pair and a 0°C or negative contribution to each mismatched base pair present in the oligonucleotide primer pair. It will be understood by those of skill in the art that the position of mismatched base pairs in the primer pairs of the present invention (i.e., 5 1 , 3• or middle) which are not 100% complementary will also effect the melting temperature.
  • sequence of the linker pair is selected from the group consisting of:
  • NANB 15 5'AGCAGGCAGAAGTATGCAAA 3' NANB 16 3 • TCGTCCGTCTTCATACGTTT 5', NANB 19 5 » TAAGTAGGTGAGTAAGTGAG 3' NANB 20 3'ATTCATCCACTCATTCACTC 5 1 , and
  • the primer pair is PCR 01/PCR 02.
  • the melting temperature of PCR 01/PCR 02 is about 60°C.
  • self-complementarity refers to the ability of one molecule of an individual primer pair member to hydrogen bond to a second molecule of the same primer pair member to form double-stranded DNA. Self-complementarity is most often characterized by the presence of a restriction endonuclease site in the sequence of the oligonucleotide primer pair member.
  • primer pair member When self-complementarity exists at the 3 ' end of a primer pair member, the annealing of two molecules of that primer pair member creates an appropriate substrate for DNA polymerase (i.e., a template and a primer) . Because primer pair members are present in great excess over target DNA in the methods of the present invention, the above undesirable substrates rapidly consume the deoxynucleoside triphosphate molecules, resulting in drastically reduced efficiency of target DNA amplification.
  • DNA polymerase i.e., a template and a primer
  • Self-complementarity at either the 5• end or in the middle of a primer pair member is not detrimental to the methods of this invention.
  • the double-stranded DNA molecule formed by the annealing of two molecules of a primer pair member displaying such self-complementarity is not a substrate for DNA polymerase.
  • the term "significant self- complementarity" refers to that type of self- complementarity which would favor the annealing of individual molecules of a primer pair member to one another so as to create a DNA polymerase substrate.
  • the 5 1 ends of the primer pair should be non-phosphorylated.
  • the absence of phosphorylation prevents the ligation of the linker pairs or individual primer pair members to each other.
  • a structure which consists solely of concatamers of oligonucleotide primer pairs would create a substrate for DNA polymerase during the melting and reannealing steps of the methods of this invention. Such a reaction is undesirable because it dramatically decreases the efficiency of the amplification reaction.
  • oligonucleotide primer pairs of this invention may be synthesized by any standard method known in the art. Preferably, both first and second strands of the primer pair are synthesized separately, using an automated oligonucleotide synthesizer.
  • the methods of the present invention require the presence of double-stranded target DNA in order to carry out amplification. Once the target DNAs have been isolated, the next step is to ligate on the primer pair. Because the amplification methods of the present invention require the ligation of the primer pair onto the target DNA by blunt-end ligation, the target DNA should first be rendered blunt-ended. This may be achieved by any conventional method, including the use of restriction enzymes which produce blunt ends, as well as by single-strand specific exonucleases which generate blunt ends from overhangs previously produced by restriction enzymes, or enzymes used in the synthesis of cDNA. It will be obvious that the need for blunt- ending is obviated if the target DNA is initially present as a blunt-ended molecule.
  • the optimum concentration of primer pair used in the ligation reaction will range from about 1 femtomole to about 1 picomole/ ⁇ l of reaction mix. In addition, the concentration of primer pair is ideally many-fold greater than that of the target DNA.
  • Ligation may be performed by any number of conventional techniques. Because the primer pair is not phosphorylated, the products of the ligation will consist of a first primer pair member covalently attached to the blunt 5 • terminus of the target fragments and the second primer pair member annealed to the first primer pair member via hydrogen bonding, but not covalently attached to the 3' terminus of the target DNAs.
  • the primer pairs may be oriented in either direction at either end of the target DNAs, resulting in four possible combinations:
  • (bottom) represent the two different members of the primer pair; 5' and 3* represent the orientation of the _ primer pair and ⁇ represents a covalent phosphodiester bond between the target DNA and the 3' ends of the primer pair.
  • the actual amplification step of the methods of this invention is initiated by adding an excess quantity of only one member of the primer pair.
  • Those of skill in the art will recognize that only one of the above four molecules may actually be amplified (either (2) or (3) depending on whether the "top” or “bottom” primer pair member is used for initiation of amplification) . This is of little consequence, however, since the amount of target DNA increases exponentially during each amplification step.
  • the unbonded member of the primer pair is melted off and replaced by an identical sequence that is covalently bonded to the target DNAs.
  • This is preferably achieved by raising the temperature of the solution containing the linkered target DNA to a point at which the unbonded pair member melts off and then performing a 3' extension reaction.
  • the temperature of the solution should not, however, be raised high enough to cause a melting of the strands of the target DNAs. It is therefore desirable to heat the solution to a temperature above the melting temperature (T Ti) of the primer pair, but below the T. of the target DNA.
  • T Ti melting temperature
  • the ionic strength of the solution may also affect the ⁇ increment.
  • the T. of most target DNAs will be at least 75°C. It is therefore preferable to use a primer pair that has a melting temperature below about 70°C and to effect the melting of the primer pair by heating to about 72°C.
  • the melting reaction is essentially complete after about 5 minutes. Once the unbonded pair member is melted off, the resulting 5' overhangs are repaired by standard 3 ' extension means. This involves contacting the sample with a mixture of four deoxynucleotide triphosphates (dATP, dCTP, dTTP and dGTP) and a DNA polymerase, preferably a thermostable polymerase, such as Tag.
  • the extension reaction is preferably performed at about 72°C.
  • the 3 1 extension reaction is preferably carried out in the presence of an excess amount of the one of the members of the primer pair that will be used to initiate PCR.
  • the added primer pair member does not participate in the 3" extension reaction, it is preferably included at this step in preparation for the subsequent polymerase chain reaction step.
  • the primer pair member may be added following the 3' extension reaction.
  • the amount of primer pair member added at this step is at least 10- fold greater and preferably at least 20-fold greater than the amount of primer pair added in the ligation reaction. This will allow. subsequent amplification of the linkered target DNA in the polymerase chain reaction steps that follow.
  • the melting off and 3* extension steps are performed simultaneously and in the presence of an excess amount of one of the primer pair members. This is achieved by adding the primer pair member, the DNA polymerase and the four deoxynucleotide triphosphates prior to or during the melting off step.
  • PCR is initiated following completion of the extension reaction by adding an effective amount of a primer pair member, an effective amount of a DNA polymerase and an effective amount of the four different nucleotide triphosphates.
  • the PCR reaction utilizes the primer pair member, deoxynucleotide triphosphates and DNA polymerase already present in the samples from the 3' extension step.
  • the sample is heated to a temperature above the T Tin of the target DNA.
  • the sample is heated to about 93°C to insure complete melting of the linkered target DNA strands.
  • the duration of this heating should preferably be kept to a minimum effective time, most preferably about 2 minutes.
  • the sample is then cooled, preferably to about 40°C, to allow hybridization of the excess added primer pair member to its complementary sequence present on the linkered target DNA. Preferably, this step will also be complete in about 2 minutes.
  • the sample is then reheated to a temperature which promotes primer extension, resulting in an effective doubling of the amount of properly primed target DNAs.
  • the temperature at which primer extension is performed must be lower than the T Tin of the target DNAs and, when Tag polymerase is employed, is preferably about 72°C.
  • the duration of the primer extension step will vary depending on the length of the target DNA.
  • the duration of the primer extension step is approximated at about 1 minute per kilobase length of target DNA. In most situations, the primer extension reaction is completed in about 4 to about 6 minutes. The melting, annealing and primer extension steps are then repeated as many times as is necessary to produce a desired amount of target DNA. These steps or their equivalents, which result in the amplification of target DNA, are collectively referred to as "PCR means".
  • the amount of target DNA produced may be estimated by the formula: where X equals the amount of amplifiable target DNA sequence initially present and n equals the number of PCR cycles performed.
  • the techniques for initially obtaining the target DNA will vary depending upon the nature of the original sample.
  • the target DNA is a collection of cDNAs synthesized from a small tissue sample or a single cell
  • the first step is the isolation of mRNA from that sample.
  • This technique is well known in the art.
  • small tissue sample refers to an amount of a biological sample which does not contain enough mRNA to produce clonable quantities of cDNA. Small tissue samples are exemplified by biopsy samples.
  • first- and second-strand cDNA synthesis is performed, preferably employing a cDNA synthesis kit (e.g., BRL cDNA Synthesis System, Bethesda Research Laboratories, Bethesda, Maryland) .
  • the sequence-independent gene amplification methods of this invention may then be used to produce clonable amounts of the resultant cDNA molecules.
  • Restriction enzyme site-containing linkers or polynucleotide linkers may then be ligated onto the ends of the cDNAs following the amplification reaction.
  • the oligonucleotide primer pair will itself contain an internal restriction site, located either in the middle or at the 5' end, obviating the need for additional linkers.
  • the original sample to be amplified consists of nucleic acid sequences obtained from a suspected infectious agent which is present in an intractable titer in the infected host.
  • a biological sample containing the presumptive causative agent is obtained, homogenized if necessary, and treated with a nuclease, preferably micrococcal nuclease, to digest the host's nucleic acid sequences.
  • the nuclease is then inactivated by any of a number of well known procedures including, but not limited to, heating, addition of metal chelaters, such as EGTA, and extraction with organic solvents, s ⁇ uch as phenol.
  • the causative agent's nucleic acid sequences are then isolated.
  • Isolation of nucleic acid sequences from the causative agent initially involves destruction of the viral envelope. This may be achieved with a variety of reagents including organic solvents, preferably phenol, lipases, and proteases.
  • the nucleic acids may then be isolated by standard techniques. Most preferably, inactivation of the nuclease and dissolution of the viral envelope are achieved in a single step by phenol extraction.
  • the isolated nucleic acid sequences remain in the aqueous phase which may be used directly"in the methods of this invention or following precipitation and concentration. It should be obvious that precipitation of the small amount of nucleic acid sequences may be facilitated by the addition of a carrier molecule.
  • the carrier ' molecule is a mixture of short, random sequence oligonucleotides.
  • viral nucleic acid sequences may be in the form of single-stranded or double-stranded DNA or RNA. Additionally, the nucleic acid sequences may be circular or linear. In order to amplify the nucleic acid sequences from an infectious agent without first identifying their structure it is preferable that double-stranded cDNA be synthesized from the isolated nucleic acid sequences. Because cDNA synthesis requires single-stranded nucleic acid sequences as templates, the isolated nucleic acid sequences should initially be denatured. Boiling the isolated nucleic acid sample is most preferable because it will denature both linearized and nicked, circular double-stranded nucleic acids, while having no deleterious effect on single-stranded nucleic acids.
  • the boiling step is likely to introduce random nicks into each strand at low frequency. These nicked molecules will then denature. Therefore, this treatment insures the production of single-stranded nucleic acids no matter what the nature of the starting material.
  • cDNA synthesis may then be achieved from the resulting single-stranded nucleic acids by methods which are known to those of skill in the art.
  • the double-stranded cDNA is an appropriate target DNA for the methods of this invention. It should also be understood that isolated nucleic acids that are known to exist as linear double-stranded DNA molecules may be amplified directly by the methods of this invention without the need for synthesizing linear double-stranded cDNA.
  • Still another embodiment of the present invention relates to amplifying DNA inserts contained within an isolated recombinant clone.
  • This aspect of the invention is especially useful when the target DNA is cloned into a vector, such as a bacteriophage, which cannot be replicated readily into large quantities.
  • a vector such as a bacteriophage
  • This method surprisingly allows those of skill in the art to produce useful quantities of these DNA inserts without the need for subcloning into a more suitable vector.
  • the vector containing the DNA insert desired to be amplified is isolated from the host which harbors it. Such methods are well known and are commonly used in the art.
  • the vector is then cleaved with a restriction enzyme which will release the inserted target DNA from the vector.
  • the released target DNA and the remaining vector may then be amplified in solution together and subsequently separated on the basis of size (invariably the vector will be substantially larger than the target DNA) .
  • I further purified the individual oligonucleotide primer pair members by electrophoresis in a 10 well, 1.5 mm thick, 20% polyacrylamide gel containing 7 M urea.
  • I dissolved the contents of one Eppendorf tube in 40 ⁇ l of 7 M urea and loaded 10 ⁇ l of the mixture into each of four wells in the gel. The samples were then electrophoresed for approximately 2 hours at 500 volts. I then removed the gel from the glass plates and wrapped it in plastic wrap. The electrophoresed oligonucleotide was visualized under ultraviolet light using a fluorescent TLC plate as a background (Whatman, Maidstone, Kent, England) . Bands containing the oligonucleotide were excised from the gel and placed into an Eppendorf centrifuge tube.
  • the oligonucleotide was then eluted from the gel slice by adding just enough 10 mM triethylammonium bicarbonate, pH 7.6, to cover the excised gel slice and incubating at 50°C for 3 hours.
  • the eluted material was then loaded onto a 1 ml disposable C18 column (J. T. Baker, Phillipsburg, NJ) .
  • the column had been previously washed with 10 ml of HPLC grade acetonitrile followed by 10 ml of H_0. .
  • H O 10 ml of H O.
  • the oligonucleotide was then eluted with 4 x 1 ml of 20% acetonitrile in H O.
  • the DNA eluted in the first two 20% acetonitrile fractions as determined spectrophoto etrically at 260 nm.
  • the fractions containing the oligonucleotide were concentrated to dryness in a Speed-Vac Concentrator.
  • the oligonucleotide was then dissolved in 1 ml of H-O.
  • the final concentration of oligonucleotide was determined by measuring the absorbance at 260 nm.
  • the oligonucleotide solution was stored at -20°C until used.
  • the final yield of both PCR 01 and PCR 02 was 1.4 OD units (64 ⁇ g) .
  • the target DNAs used to test the method of this invention were Vietnamese fragments of the plasmid RSD (PCT patent application WO 88/00831) .
  • Figure 1 displays the results of this analysis.
  • Figure 1, lane 1 depicts 0.5 ⁇ g of unamplified test fragments.
  • Figure 1, lanes 2 and 3 depict the 1/lOth of the product of amplifying 10 picograms of test fragments for 60 cycles using PCR 01 or PCR 02, respectively, as primers.
  • Insulin-dependent diabetes mellitus is a disease whose cause is unknown.
  • the suspected causative agent may be a virus present at an intractable titer [G. T. Horn et al., Proc. Natl. Acad. Sci. USA. 85, pp. 6012-16 (1988)].
  • the methods of this invention are applied to a blood sample of a patient developing IDDM to detect and analyze the nucleic acids of this suspected virus.
  • a sample of blood is collected from a patient recently diagnosed as having IDDM.
  • the blood is collected with a large bore needle into anticoagulant- free Vacutainers (Becton-Dickinson, Rutherford, NJ) .
  • Cells and fibrin clots are removed by centrifuging at 2,000 rpm for 20 minutes at 4°C.
  • One ml of the serum is treated with 10 ⁇ g of micrococcal nuclease (Pharmacia, Piscataway, New Jersey) for 1 hour at 37°C to digest any free nucleic acid that may be contained in the serum.
  • Nucleic acids from the suspected enveloped virus are liberated into solution by adding 5 ⁇ l of 1M DTT and 1000 units of RNasin (Promega, Madison, Wisconsin) and then extracting twice with phenol.
  • the aqueous phase is collected and 1 ⁇ l of synthetic primer, pd(N) 6 , (at a concentration of 50 OD units/ml; Pharmacia) is added.
  • the synthetic primer, pd(N) 6 is used to randomly prime first strand cDNA synthesis as well as serving as a carrier during subsequent precipitation of the rare viral nucleic acids.
  • the nucleic acids are then ethanol precipitated, dried and redissolved in 30 ⁇ l of H 2 0. , The sample is then denatured by boiling for 3 minutes. Renaturation is prevented by quickly chilling the boiled sample on ice.
  • Double-stranded cDNA is then synthesized from the denatured nucleic acids using a cDNA kit (Bethesda Research Laboratories, Bethesda, Maryland) following the manufacturer's instructions.
  • the resulting cDNA is isopropanol precipitated, redissolved and then ethanol precipitated.
  • the ethanol precipitate is dissolved in 20 ⁇ l of IX T4 DNA ligase buffer containing 2 picomoles each of PCR 01 and PCR 02 and 8 units of T4 ligase.
  • Ligation is achieved by incubating the sample overnight at 15°C.
  • the linkered cDNAs are digested with Notl. which cleaves in the middle of the PCR 01/PCR 02 primer pair, and ligated into a Notl- digested expression vector. Individual clones are plated and screened with antisera obtained from a patient suffering from IDDM. While we have hereinbefore represented a number of embodiments of this invention, it is apparent that our basic construction can be altered to provide other embodiments which utilize the processes of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the claims appended hereto rather than the specific embodiments which have been presented hereinbefore by way of example.

Landscapes

  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
EP19900906003 1989-02-14 1990-02-14 Oligonukleotid-primer-paare zur amplifizierung eines gens, unabhängig von der sequenz und verfahren zu deren verwendung Withdrawn EP0458909A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31076389A 1989-02-14 1989-02-14
US310763 1989-02-14

Publications (1)

Publication Number Publication Date
EP0458909A1 true EP0458909A1 (de) 1991-12-04

Family

ID=23203992

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19900906003 Withdrawn EP0458909A1 (de) 1989-02-14 1990-02-14 Oligonukleotid-primer-paare zur amplifizierung eines gens, unabhängig von der sequenz und verfahren zu deren verwendung

Country Status (4)

Country Link
EP (1) EP0458909A1 (de)
AU (1) AU5404890A (de)
CA (1) CA2046919A1 (de)
WO (1) WO1990009457A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE144556T1 (de) * 1988-06-24 1996-11-15 Amgen Inc Verfahren und mittel zum nachweis von nukleinsäuresequenzen
GB8818020D0 (en) * 1988-07-28 1988-09-01 Ici Plc Method for amplification of nucleotide sequences
EP0545459A1 (de) * 1989-01-31 1993-06-09 The Regents Of The University Of California Amplifikation von Durchflusszytrometrie sortiertes DNS
EP0456721A4 (en) * 1989-01-31 1992-06-03 University Of Miami Microdissection and amplification of chromosomal dna
WO1992002642A1 (en) * 1990-08-10 1992-02-20 Chiron Corporation Nanbv diagnostics: polynucleotides useful for screening for hepatitis c virus
FR2678639B1 (fr) * 1991-07-03 1993-09-17 Rhone Poulenc Rorer Sa Procede de clonage d'acides nucleiques.
US5422252A (en) * 1993-06-04 1995-06-06 Becton, Dickinson And Company Simultaneous amplification of multiple targets
US5710000A (en) 1994-09-16 1998-01-20 Affymetrix, Inc. Capturing sequences adjacent to Type-IIs restriction sites for genomic library mapping
EP1047794A2 (de) * 1998-01-13 2000-11-02 BioChip Technologies GmbH Verfahren zum nachweis von nukleinsäuresequenzen
DE10108626A1 (de) * 2001-02-22 2002-09-05 Sahin Ugur Verfahren zur Identifizierung biologisch aktiver Strukturen mikrobieller Erreger

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
IL86724A (en) * 1987-06-19 1995-01-24 Siska Diagnostics Inc Methods and kits for amplification and testing of nucleic acid sequences
US6107023A (en) * 1988-06-17 2000-08-22 Genelabs Technologies, Inc. DNA amplification and subtraction techniques
EP0426756A4 (en) * 1988-07-26 1991-11-21 Genelabs Incorporated Rna and dna amplification techniques
AU3974989A (en) * 1988-07-26 1990-02-19 Genelabs Incorporated Sequence-specific amplification techniques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9009457A2 *

Also Published As

Publication number Publication date
AU5404890A (en) 1990-09-05
WO1990009457A2 (en) 1990-08-23
WO1990009457A3 (en) 1990-10-04
CA2046919A1 (en) 1990-08-15

Similar Documents

Publication Publication Date Title
US5366877A (en) Restriction/ligation labeling for primer initiated multiple copying of DNA ssequences
EP0593095B1 (de) Genomische Klonierung und Kartographie
JP4289443B2 (ja) Ｐｃｒの過程でｄｎａ断片の増幅を抑制する方法
US5487993A (en) Direct cloning of PCR amplified nucleic acids
US5731171A (en) Sequence independent amplification of DNA
US5830643A (en) Partially double-stranded oligonucleotide and method for forming oligonucleotide
AU647411B2 (en) Enhanced nucleic acid amplification process
US6114149A (en) Amplification of mixed sequence nucleic acid fragments
JP2954232B2 (ja) 核酸配列の増幅および検出法
JP3421664B2 (ja) ヌクレオチド塩基の同定方法
CN114174535B (zh) Crispr多靶标检测方法及其试剂盒
US20060068394A1 (en) Method of producing a DNA library using positional amplification
JPH02503054A (ja) 核酸配列の増幅および検出
JP3403405B2 (ja) 核酸伸長検定
CA2467577A1 (en) Multiplex pcr
JPH0634759B2 (ja) テンプレート−依存性核酸プロ−ブ再構成を用いたアッセイ
JPH074248B2 (ja) 核酸増幅反応の汚染を制御する方法
CA3096856A1 (en) Method for selectively adapting a polynucleotide
US6962780B2 (en) Method for synthesis of nucleic acids
EP0458909A1 (de) Oligonukleotid-primer-paare zur amplifizierung eines gens, unabhängig von der sequenz und verfahren zu deren verwendung
WO1990001064A1 (en) Sequence-specific amplification techniques
JP3883476B2 (ja) 核酸配列の増幅方法
JPH099967A (ja) 核酸合成法
JP4186269B2 (ja) 核酸合成法
JPH09187277A (ja) 鋳型として全血液を用いた核酸の直接的ｐｃｒ増幅法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19910813

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19920227